[go: up one dir, main page]

MX2021000304A - Terapias combinadas dirigidas a cd38 y tgf-beta. - Google Patents

Terapias combinadas dirigidas a cd38 y tgf-beta.

Info

Publication number
MX2021000304A
MX2021000304A MX2021000304A MX2021000304A MX2021000304A MX 2021000304 A MX2021000304 A MX 2021000304A MX 2021000304 A MX2021000304 A MX 2021000304A MX 2021000304 A MX2021000304 A MX 2021000304A MX 2021000304 A MX2021000304 A MX 2021000304A
Authority
MX
Mexico
Prior art keywords
tgf
beta
combined therapies
therapies directed
directed
Prior art date
Application number
MX2021000304A
Other languages
English (en)
Inventor
Gary Shapiro
Richard C Gregory
Francisco Adrian
De Velde Helgi Van
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021000304A publication Critical patent/MX2021000304A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a terapias combinadas contra el cáncer dirigidas a CD38 y TGF-ß que utilizan anticuerpos específicos para estas dianas. También se proporcionan composiciones útiles en las terapias.
MX2021000304A 2018-07-10 2019-07-10 Terapias combinadas dirigidas a cd38 y tgf-beta. MX2021000304A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696198P 2018-07-10 2018-07-10
EP19305470 2019-04-11
PCT/IB2019/055885 WO2020012383A1 (en) 2018-07-10 2019-07-10 Combination therapies against cancer targeting cd38 and tgf-beta

Publications (1)

Publication Number Publication Date
MX2021000304A true MX2021000304A (es) 2021-04-12

Family

ID=69141688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000304A MX2021000304A (es) 2018-07-10 2019-07-10 Terapias combinadas dirigidas a cd38 y tgf-beta.

Country Status (13)

Country Link
US (1) US20210155708A1 (es)
EP (1) EP3820575A1 (es)
JP (2) JP7636177B2 (es)
KR (1) KR20210030411A (es)
AU (2) AU2019301283B2 (es)
BR (1) BR112021000065A2 (es)
CA (1) CA3105333A1 (es)
CO (1) CO2021000015A2 (es)
IL (1) IL279935A (es)
MX (1) MX2021000304A (es)
SG (1) SG11202012991QA (es)
TW (1) TW202019962A (es)
WO (1) WO2020012383A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
CA2930677A1 (en) * 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
LT2714735T (lt) 2011-06-03 2021-12-10 Xoma Technology Ltd. Tgf beta specifiniai antikūnai
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
RU2670127C2 (ru) * 2013-03-13 2018-10-18 Санофи Композиции, включающие антитела к cd38 и карфилзомиб
JP6483086B2 (ja) 2013-03-20 2019-03-13 ジェンザイム・コーポレーション 骨形成不全症の処置方法
EP3571227A1 (en) 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use
TW202506185A (zh) * 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
JP2022532356A (ja) * 2019-05-14 2022-07-14 サノフイ 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法
CA3160502A1 (en) * 2019-12-05 2021-06-10 Thomas Ballet Formulations of anti-cd38 antibodies for subcutaneous administration

Also Published As

Publication number Publication date
KR20210030411A (ko) 2021-03-17
AU2019301283B2 (en) 2024-12-19
TW202019962A (zh) 2020-06-01
US20210155708A1 (en) 2021-05-27
JP2025081424A (ja) 2025-05-27
JP2021530461A (ja) 2021-11-11
AU2019301283A1 (en) 2021-02-04
IL279935A (en) 2021-03-01
CN112703038A (zh) 2021-04-23
WO2020012383A1 (en) 2020-01-16
CO2021000015A2 (es) 2021-04-08
AU2025201957A1 (en) 2025-04-10
SG11202012991QA (en) 2021-01-28
BR112021000065A2 (pt) 2021-04-06
JP7636177B2 (ja) 2025-02-26
EP3820575A1 (en) 2021-05-19
CA3105333A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2019003657A1 (es) Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275)
MX2020005701A (es) Células efectoras inmunitarias potenciadas y usos de las mismas.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CL2023002048A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos
MX389945B (es) Anticuerpos anti-pd-1 y sus metodos de uso.
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2018001644A (es) Anticuerpos anti-pd-1 novedosos.
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
UY35961A (es) Anticuerpos y fragmentos anti-vista
CU20110029A7 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CL2018002793A1 (es) Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control
MX2025003354A (es) Anticuerpos que se unen a 5t4
CO2020012593A2 (es) Derivados de oxadiazolina
CU20210096A7 (es) Moléculas de unión a cd19
CO2019006424A2 (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2019003557A1 (es) Anticuerpos anti-trkb.